Skip to main content

TL1A Inhibitor Deal Benchmarks in Immunology & Autoimmune

Median Upfront
$676M
Range: $359M - $979M
Total Deal Value
$3.5B
Range: $2.2B - $4.9B
Royalty Rate
14.7% - 24.5%
Tiered up to 28.5%
Dev Milestones
$570M
Range: $365M - $777M
Model Your Deal

Market Analysis

TL1A Inhibitor therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 tl1a inhibitor asset in immunology & autoimmune is $676M, with total deal values reaching $3.5B. Development milestones average $570M, while regulatory milestones contribute $997M.

The immunology & autoimmune tl1a inhibitor landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for tl1a inhibitor immunology & autoimmune deals range from 14.7% to 24.5% at the base tier, with tiered escalation reaching 18.7%-28.5% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a tl1a inhibitor immunology & autoimmune licensing deal?
Based on our analysis, Phase 2 tl1a inhibitor licensing deals in immunology & autoimmune average $676M in upfront payments, with a range of $359M to $979M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for tl1a inhibitor immunology & autoimmune transactions?
The median total deal value for Phase 2 tl1a inhibitor assets in immunology & autoimmune is $3.5B, ranging from $2.2B to $4.9B. This includes development milestones ($570M), regulatory milestones ($997M), and commercial milestones ($1.3B).
What royalty rates are standard for tl1a inhibitor deals in immunology & autoimmune?
Base royalty rates for tl1a inhibitor immunology & autoimmune transactions range from 14.7% to 24.5%, with tiered escalations reaching 18.7%-28.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in tl1a inhibitor immunology & autoimmune deals?
TL1A Inhibitor immunology & autoimmune deals allocate approximately 81% of total deal value to milestones. Development milestones ($570M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($997M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

TL1A Inhibitor in Gastroenterology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included